Reasons for SB2 in switched cohort and historical OI cohort
| Groups | Follow-up | n | Number of withdrawals | Reasons for discontinuation | Treatment after discontinuation |
|---|---|---|---|---|---|
| OI to SB2 | 34 weeks | 45 | 4 | NE (pain, fatigue) synovitis (present before switch) Uveitis Suspicion of demyelinating disorder (symptoms present before switch) | Backswitch to OI Adalimumab Adalimumab Secukinumab |
| 1 year | 41 | 3 | Uveitis NE (end of dose wear-off) NE (fatigue) | Backswitch to OI Backswitch to OI Backswitch to OI | |
| Historical OI | 34 weeks | 52 | 2 | Loss of efficacy NSAE | Istekinumab Certolizumab |
| 1 year | 50 | 4 | Loss of efficacy End of dose wear-off Loss of efficacy and ADA Loss of efficacy | Abatacept Golimumab Cosentyx Golimumab |